Kiniksa Pharmaceuticals International, plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNSA research report →
Range $74 – $115
Price Chart
About the company
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
- CEO
- Sanj K. Patel
- IPO
- 2018
- Employees
- 366
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on KNSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.38B
- P/E
- 66.26
- Fwd P/E
- 61.78
- PEG
- 0.35
- P/S
- 7.87
- P/B
- 10.43
- EV/EBITDA
- 51.15
- Div Yield
- 0.00%
- Gross Margin
- 54.26%
- Op Margin
- 13.79%
- Net Margin
- 11.58%
- ROE
- 17.27%
- ROIC
- 12.30%
Latest fiscal year · YoY change
- Revenue
- $677.56M+60.1%
- Gross Profit
- $370.15M+2.2%
- Op Income
- $77.22M
- Net Income
- $59.01M+236.6%
- EPS
- $0.80+233.3%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $99.31
- 52W Low
- $37.02
- 50D MA
- $83.54
- 200D MA
- $63.83
- Beta
- 0.08
- RSI (14)
- 56
- Avg Volume
- 660.24K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kiniksa topped $286 million in Q3 ARCALYST revenue, raised 2026 revenue guidance above $1 billion, and highlighted continued commercial momentum plus advancing late-stage and early-stage pipeline work.· October 27, 2026
- Q3 ARCALYST revenue was $286 million, up 58% year over year, with operating income of $54.2 million and net income of $47.3 million.
- The company raised full-year 2026 revenue guidance to $1.045 billion-$1.050 billion and also guided full-year R&D to $160 million-$170 million and SG&A to $270 million-$280 million.
- Management said ARCALYST penetration in the multiple-recurrence population reached 23% at quarter-end, with about 5,450 total prescribers and continued adoption earlier in the disease course.
- KPL-387 pivotal data are now expected in the second half of 2027, while KPL-1161 remains on track to enter phase I by the end of 2026.
- Cash ended the quarter at $568.8 million, including about $43 million of net cash generation in the quarter.
Kiniksa reported Q3 2026 ARCALYST revenue of $286 million, up 58% year over year. Operating income was $54.2 million and net income was $47.3 million, both up significantly year over year. ARCALYST collaboration profit rose 67% year over year to $211.6 million. Cash and cash equivalents were $568.8 million at quarter-end, reflecting approximately $43 million of net cash generation in the quarter. Looking ahead, management raised 2026 ARCALYST revenue guidance to $1.045 billion-$1.050 billion. Full-year 2026 R&D expense guidance is $160 million-$170 million, and SG&A is $270 million-$280 million.
Sanj K. Patel emphasized that Kiniksa is building a broader IL-1 alpha and beta inhibition franchise, led by ARCALYST in recurrent pericarditis and supported by KPL-387 and KPL-1161. He said the company is seeing robust growth, improved market penetration, and strong execution from commercial and clinical teams, while continuing to invest for future value creation. His tone was upbeat and confident, repeatedly stressing long-term opportunity and disciplined capital allocation.
Mark Ragosa focused on the quarter’s financial strength: ARCALYST revenue growth, operating income of $54.2 million, net income of $47.3 million, and collaboration profit of $211.6 million. He highlighted that higher operating expenses were driven by ARCALYST commercialization, KPL-387 development, and added SG&A, but the business still generated approximately $43 million of net cash in the quarter. He also gave specific 2026 spending guidance: R&D at $160 million-$170 million, including fourth-quarter KPL-387 pre-commercial manufacturing costs, and SG&A at $270 million-$280 million to support commercialization and disease awareness.
Analysts focused on KPL-387 enrollment, the new second-half 2027 pivotal data timing, and what that means for a potential launch; management said the global study is enrolling and dosing patients and that site engagement and investigator enthusiasm are strong. Questions also centered on the penetration curve and how much additional SG&A and DTC spending is needed to drive more scripts; Ross Moat said the spend is highly targeted and efficient, and that there is still substantial opportunity in both multiple-recurrence and first-recurrence patients. On the pipeline, management said KPL-387 transition data are designed to inform labeling for monotherapy switching, while KPL-1161 is expected to begin phase I by year-end with indication plans not yet disclosed. A final question on cash deployment and BD drew a response that Kiniksa is open to external opportunities but keeps the bar high and remains highly disciplined on capital allocation.
The quarter showed that ARCALYST continues to scale profitably, with strong year-over-year revenue and collaboration profit growth and expanding prescriber counts. Management also sounded confident that the market is still early in penetration, with only 23% penetration in the multiple-recurrence group and signs that physicians are moving earlier in the treatment pathway.
The upside case still depends heavily on a single commercial product, even as operating expenses rise to support further penetration. KPL-387 remains years from potential launch, with pivotal data not expected until the second half of 2027, and KPL-1161 is still early enough that management has not disclosed an indication strategy.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.6%
- Shares Outstanding
- 78.57M
- Float Shares
- 75.12M
of shares held by institutions
276 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 7.49M | ▲ 516.03K |
| Rubric Capital Management LP | 4.00M | ▲ 249.80K |
| Vanguard Group Inc | 3.11M | ▲ 49.80K |
| Blackrock, Inc. | 2.94M | ▲ 204.06K |
| Baker Bros. Advisors LP | 2.83M | ▲ 8.40K |
| Tang Capital Management LLC | 2.26M | 0 |
| Vanguard Portfolio Management LLC | 2.03M | ▲ 119.33K |
| Vanguard Capital Management LLC | 1.43M | ▲ 72.84K |
| Arrowstreet Capital, Limited Partnership | 1.09M | ▲ 136.42K |
| Morgan Stanley | 936.37K | ▼ 74.77K |
| State Street Corp | 926.27K | ▲ 222.07K |
| Spruce Street Capital LP | 918.07K | 0 |
Held by 331 ETFs
Biggest fund positions in KNSA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Paolini John F. | other | 2,595 |
| Nov 13, 26 | Paolini John F. | other | 3,144 |
| Nov 13, 26 | Paolini John F. | other | 3,723 |
| Nov 13, 26 | Paolini John F. | other | 4,994 |
| Nov 13, 26 | Paolini John F. | other | 29,670 |
| Nov 13, 26 | Paolini John F. | other | 3,723 |
| Nov 13, 26 | Paolini John F. | other | 4,994 |
| Nov 13, 26 | Paolini John F. | other | 2,595 |
| Nov 13, 26 | Paolini John F. | other | 3,144 |
| Nov 13, 26 | Paolini John F. | other | 29,670 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KNSA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on KNSA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Top Momentum Stock for the Long-Term
zacks.com · Nov 20
Kiniksa Pharmaceuticals International, plc $KNSA Stock: Aberdeen Group plc Reduces Stake
defenseworld.net · Nov 17
74,458 Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Fisher Asset Management LLC
defenseworld.net · Nov 15
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 11
AlphaCentric Advisors LLC Acquires New Position in Kiniksa Pharmaceuticals International, plc $KNSA
defenseworld.net · Nov 7
Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock
zacks.com · Nov 4
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
fool.com · Oct 27
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
marketbeat.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
